Wall Street analysts forecast that Illumina, Inc. (NASDAQ:ILMN) will announce $1.19 earnings per share for the current quarter, Zacks reports. Seven analysts have issued estimates for Illumina’s earnings. The highest EPS estimate is $1.25 and the lowest is $1.16. Illumina reported earnings of $0.85 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 40%. The firm is expected to announce its next quarterly earnings report on Tuesday, January 30th.
On average, analysts expect that Illumina will report full year earnings of $3.76 per share for the current fiscal year, with EPS estimates ranging from $3.73 to $3.82. For the next fiscal year, analysts anticipate that the company will report earnings of $4.51 per share, with EPS estimates ranging from $4.20 to $4.82. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Illumina.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business’s revenue for the quarter was up 17.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.97 earnings per share.
Illumina (ILMN) traded up $4.68 during trading hours on Friday, reaching $244.72. The company’s stock had a trading volume of 975,800 shares, compared to its average volume of 900,526. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $35,730.00, a price-to-earnings ratio of 46.17, a price-to-earnings-growth ratio of 3.23 and a beta of 0.79. Illumina has a 12-month low of $156.50 and a 12-month high of $245.96.
In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction on Tuesday, October 24th. The stock was sold at an average price of $210.43, for a total transaction of $4,208,600.00. Following the transaction, the director now owns 539,176 shares in the company, valued at approximately $113,458,805.68. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Marc Stapley sold 2,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $205.48, for a total value of $410,960.00. Following the transaction, the executive vice president now owns 30,370 shares in the company, valued at approximately $6,240,427.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 137,671 shares of company stock worth $29,485,768. 0.89% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of ILMN. Federated Investors Inc. PA increased its stake in Illumina by 46.2% during the 2nd quarter. Federated Investors Inc. PA now owns 3,704 shares of the life sciences company’s stock worth $642,000 after acquiring an additional 1,171 shares during the period. Neuberger Berman Group LLC boosted its holdings in shares of Illumina by 35.7% in the 2nd quarter. Neuberger Berman Group LLC now owns 4,893 shares of the life sciences company’s stock valued at $849,000 after purchasing an additional 1,286 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Illumina in the 2nd quarter valued at $226,000. Eaton Vance Management boosted its holdings in shares of Illumina by 0.5% in the 2nd quarter. Eaton Vance Management now owns 15,927 shares of the life sciences company’s stock valued at $2,764,000 after purchasing an additional 84 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Illumina by 116.5% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,520 shares of the life sciences company’s stock valued at $264,000 after purchasing an additional 818 shares in the last quarter. Hedge funds and other institutional investors own 91.60% of the company’s stock.
WARNING: “Analysts Expect Illumina, Inc. (ILMN) Will Post Earnings of $1.19 Per Share” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.com-unik.info/2018/01/13/analysts-expect-illumina-inc-ilmn-will-post-earnings-of-1-19-per-share.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Illumina? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Illumina and related companies.